Vertex Pharmaceuticals Incorporated (VRTX) : Rothschild Capital Partners added new position in Vertex Pharmaceuticals Incorporated during the most recent quarter end. The investment management firm now holds 3,888 shares of Vertex Pharmaceuticals Incorporated which is valued at $373,287 , the company said in a statement filed on Jul 26, 2016 with the SEC.Vertex Pharmaceuticals Incorporated makes up approximately 0.19% of Rothschild Capital Partners’s portfolio.
Other Hedge Funds, Including , Conning boosted its stake in VRTX in the latest quarter, The investment management firm added 20 additional shares and now holds a total of 5,740 shares of Vertex Pharmaceuticals Incorporated which is valued at $551,097. Vertex Pharmaceuticals Incorporated makes up approx 0.02% of Conning’s portfolio. Seven Bridges Advisors sold out all of its stake in VRTX during the most recent quarter. The investment firm sold 1,196 shares of VRTX which is valued $114,828.Winslow Evans Crocker boosted its stake in VRTX in the latest quarter, The investment management firm added 1 additional shares and now holds a total of 166 shares of Vertex Pharmaceuticals Incorporated which is valued at $15,586. Investment Counsel added VRTX to its portfolio by purchasing 6,000 company shares during the most recent quarter which is valued at $546,900. Vertex Pharmaceuticals Incorporated makes up approx 0.43% of Investment Counsel’s portfolio. Franklin Street Advisors Inc Nc sold out all of its stake in VRTX during the most recent quarter. The investment firm sold 20,447 shares of VRTX which is valued $1,794,838.
Vertex Pharmaceuticals Incorporated opened for trading at $96.28 and hit $97.07 on the upside on Friday, eventually ending the session at $97, with a gain of 0.82% or 0.79 points. The heightened volatility saw the trading volume jump to 10,12,773 shares. Company has a market cap of $23,993 M.
On the company’s financial health, Vertex Pharmaceuticals Incorporated reported $0.24 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $0.20. The company had revenue of $431.61 million for the quarter, compared to analysts expectations of $429.58 million. The company’s revenue was up 159.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.54 EPS.
Many Wall Street Analysts have commented on Vertex Pharmaceuticals Incorporated. Shares were Reiterated by RBC Capital Mkts on Apr 28, 2016 to “Outperform” and Lowered the Price Target to $ 115 from a previous price target of $135 .Shares were Reiterated by Barclays on Apr 28, 2016 to “Overweight” and Lowered the Price Target to $ 110 from a previous price target of $135 .Vertex Pharmaceuticals Incorporated was Downgraded by Goldman to ” Neutral” on Apr 28, 2016.
Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering developing manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertexs business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs including programs in the areas of oncology and neurology. The Companys product candidates include KALYDECO (ivacaftor) Lumacaftor in combination with Ivacaftor VX-661 in combination with Ivacaftor VX-803 VX-970 and VX-222. The Companys product KALYDECO is available in the market.